10-Q Filing

ALIGNMENT HEALTHCARE, INC. CIK: 1832466 Q2 2022

Filing Information

Form Type	10-Q
Accession Number	`0000950170-22-014819`
Period End Date	20220630
Filing Date	20220804
Fiscal Year	2022
Fiscal Period	Q2
XBRL Instance	alhc-20220630_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 72 Income Statement 68 Cash Flow Statement 80 Stockholders Equity 38

Balance Sheet 72 line items

Line Item	Tag	Value	Unit	Period
Allowance for credit losses	`AllowanceForDoubtfulAccountsReceivableCurrent`	$177.00K	USD	Point-in-time
Allowance for credit losses	`AllowanceForDoubtfulAccountsReceivableCurrent`	$111.00K	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	100.00M	shares	Point-in-time
Cash	`Cash`	$466.60M	USD	Point-in-time
Cash	`Cash`	$453.23M	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	0.00	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Accounts receivable (less allowance for credit losses of $177 at June 30, 2022 and $111 at December 31, 2021, respectively)	`AccountsReceivableNetCurrent`	$98.03M	USD	Point-in-time
Accounts receivable (less allowance for credit losses of $177 at June 30, 2022 and $111 at December 31, 2021, respectively)	`AccountsReceivableNetCurrent`	$58.51M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$34.34M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$27.75M	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Total current assets	`AssetsCurrent`	$552.86M	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Total current assets	`AssetsCurrent`	$585.60M	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	1.00B	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$33.41M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$30.36M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	1.00B	shares	Point-in-time
Right of use asset, net	`OperatingLeaseRightOfUseAsset`	$6.57M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	187.19M	shares	Point-in-time
Right of use asset, net	`OperatingLeaseRightOfUseAsset`	$7.85M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	187.27M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	187.27M	shares	Point-in-time
Goodwill and intangible assets, net	`IntangibleAssetsNetIncludingGoodwill`	$35.12M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	187.19M	shares	Point-in-time
Goodwill and intangible assets, net	`IntangibleAssetsNetIncludingGoodwill`	$36.25M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$4.96M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$4.71M	USD	Point-in-time
Total assets	`Assets`	$666.78M	USD	Point-in-time
Total assets	`Assets`	$630.89M	USD	Point-in-time
Medical expenses payable	`MedicalExpensesPayableCurrent`	$173.87M	USD	Point-in-time
Medical expenses payable	`MedicalExpensesPayableCurrent`	$125.89M	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$17.43M	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$14.97M	USD	Point-in-time
Accrued compensation	`AccruedCompensation`	$23.93M	USD	Point-in-time
Accrued compensation	`AccruedCompensation`	$24.87M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$167.25M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$213.71M	USD	Point-in-time
Long-term debt, net of debt issuance costs	`LongTermDebtNoncurrent`	$153.93M	USD	Point-in-time
Long-term debt, net of debt issuance costs	`LongTermDebtNoncurrent`	$150.62M	USD	Point-in-time
Long-term portion of lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$6.97M	USD	Point-in-time
Long-term portion of lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$5.43M	USD	Point-in-time
Total liabilities	`Liabilities`	$324.84M	USD	Point-in-time
Total liabilities	`Liabilities`	$373.07M	USD	Point-in-time
Commitments and Contingencies (Note 12)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and Contingencies (Note 12)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, $.001 par value; 100,000,000 and 0 shares authorized as of June 30, 2022 and December 31, 2021 respectively; no shares issued and outstanding as of June 30, 2022 and December 31, 2021	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, $.001 par value; 100,000,000 and 0 shares authorized as of June 30, 2022 and December 31, 2021 respectively; no shares issued and outstanding as of June 30, 2022 and December 31, 2021	`PreferredStockValue`	-	USD	Point-in-time
Common stock, $.001 par value; 1,000,000,000 shares authorized as of June 30, 2022 and December 31, 2021; 187,271,311 and 187,193,613 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	`CommonStockValue`	$187.00K	USD	Point-in-time
Common stock, $.001 par value; 1,000,000,000 shares authorized as of June 30, 2022 and December 31, 2021; 187,271,311 and 187,193,613 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	`CommonStockValue`	$187.00K	USD	Point-in-time
Additional Paid in Capital	`AdditionalPaidInCapital`	$928.61M	USD	Point-in-time
Additional Paid in Capital	`AdditionalPaidInCapital`	$888.55M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-635.09M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-582.69M	USD	Point-in-time
Total Alignment Healthcare, Inc. stockholders' equity	`StockholdersEquity`	$306.04M	USD	Point-in-time
Total Alignment Healthcare, Inc. stockholders' equity	`StockholdersEquity`	$293.70M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$15.00K	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	-	USD	Point-in-time
Total stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$293.29M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$306.06M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$30.61M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$354.25M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$340.38M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$293.70M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$630.89M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$666.78M	USD	Point-in-time

Income Statement 68 line items

Line Item	Tag	Value	Unit	Period
Earned premiums	`PremiumsEarnedNet`	$366.18M	USD	1 Quarter
Earned premiums	`PremiumsEarnedNet`	$308.74M	USD	1 Quarter
Earned premiums	`PremiumsEarnedNet`	$711.47M	USD	2 Qtrs
Earned premiums	`PremiumsEarnedNet`	$575.74M	USD	2 Qtrs
Other	`RevenueNotFromContractWithCustomer`	$212.00K	USD	1 Quarter
Other	`RevenueNotFromContractWithCustomer`	$528.00K	USD	2 Qtrs
Other	`RevenueNotFromContractWithCustomer`	$294.00K	USD	1 Quarter
Other	`RevenueNotFromContractWithCustomer`	$294.00K	USD	2 Qtrs
Total revenues	`Revenues`	$366.47M	USD	1 Quarter
Total revenues	`Revenues`	$712.00M	USD	2 Qtrs
Total revenues	`Revenues`	$576.03M	USD	2 Qtrs
Total revenues	`Revenues`	$308.95M	USD	1 Quarter
Medical expenses	`MedicalExpenses`	$611.03M	USD	2 Qtrs
Medical expenses	`MedicalExpenses`	$525.48M	USD	2 Qtrs
Medical expenses	`MedicalExpenses`	$274.38M	USD	1 Quarter
Medical expenses	`MedicalExpenses`	$307.27M	USD	1 Quarter
Selling, general, and administrative expenses	`SellingGeneralAndAdministrativeExpense`	$135.97M	USD	2 Qtrs
Selling, general, and administrative expenses	`SellingGeneralAndAdministrativeExpense`	$61.67M	USD	1 Quarter
Selling, general, and administrative expenses	`SellingGeneralAndAdministrativeExpense`	$136.06M	USD	2 Qtrs
Selling, general, and administrative expenses	`SellingGeneralAndAdministrativeExpense`	$71.15M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$4.18M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$8.13M	USD	2 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$3.91M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$7.64M	USD	2 Qtrs
Total expenses	`OperatingExpenses`	$669.19M	USD	2 Qtrs
Total expenses	`OperatingExpenses`	$755.12M	USD	2 Qtrs
Total expenses	`OperatingExpenses`	$373.12M	USD	1 Quarter
Total expenses	`OperatingExpenses`	$349.44M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-6.65M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-40.49M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-93.16M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-43.12M	USD	2 Qtrs
Interest expense	`InterestExpense`	$8.89M	USD	2 Qtrs
Interest expense	`InterestExpense`	$4.49M	USD	1 Quarter
Interest expense	`InterestExpense`	$4.33M	USD	1 Quarter
Interest expense	`InterestExpense`	$8.58M	USD	2 Qtrs
Other expenses (income)	`OtherNonOperatingExpenseIncome`	$-59.00K	USD	1 Quarter
Other expenses (income)	`OtherNonOperatingExpenseIncome`	$383.00K	USD	2 Qtrs
Other expenses (income)	`OtherNonOperatingExpenseIncome`	$442.00K	USD	1 Quarter
Other expenses (income)	`OtherNonOperatingExpenseIncome`	$-97.00K	USD	2 Qtrs
Total other expenses	`OtherNonoperatingIncomeExpense`	$-4.27M	USD	1 Quarter
Total other expenses	`OtherNonoperatingIncomeExpense`	$-8.48M	USD	2 Qtrs
Total other expenses	`OtherNonoperatingIncomeExpense`	$-9.27M	USD	2 Qtrs
Total other expenses	`OtherNonoperatingIncomeExpense`	$-4.93M	USD	1 Quarter
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-11.58M	USD	1 Quarter
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-52.40M	USD	2 Qtrs
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-101.64M	USD	2 Qtrs
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-44.76M	USD	1 Quarter
Provision for income taxes	`IncomeTaxExpenseBenefit`	-	USD	2 Qtrs
Provision for income taxes	`IncomeTaxExpenseBenefit`	-	USD	2 Qtrs
Provision for income taxes	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
Provision for income taxes	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
Net loss attributable to Alignment Healthcare, Inc.	`NetIncomeLoss`	$-101.64M	USD	2 Qtrs
Net loss attributable to Alignment Healthcare, Inc.	`NetIncomeLoss`	$-52.40M	USD	2 Qtrs
Net loss attributable to Alignment Healthcare, Inc.	`NetIncomeLoss`	$-11.58M	USD	1 Quarter
Net loss attributable to Alignment Healthcare, Inc.	`NetIncomeLoss`	$-44.76M	USD	1 Quarter
Total weighted-average common shares outstanding - basic and diluted	`WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasicAndDiluted`	165.70M	shares	2 Qtrs
Total weighted-average common shares outstanding - basic and diluted	`WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasicAndDiluted`	176.84M	shares	1 Quarter
Total weighted-average common shares outstanding - basic and diluted	`WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasicAndDiluted`	180.08M	shares	2 Qtrs
Total weighted-average common shares outstanding - basic and diluted	`WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasicAndDiluted`	181.26M	shares	1 Quarter
Net loss per share - basic	`EarningsPerShareBasic`	$-0.61	USD	2 Qtrs
Net loss per share - basic	`EarningsPerShareBasic`	$-0.29	USD	2 Qtrs
Net loss per share - basic	`EarningsPerShareBasic`	$-0.25	USD	1 Quarter
Net loss per share - basic	`EarningsPerShareBasic`	$-0.06	USD	1 Quarter
Net loss per share - diluted	`EarningsPerShareDiluted`	$-0.25	USD	1 Quarter
Net loss per share - diluted	`EarningsPerShareDiluted`	$-0.61	USD	2 Qtrs
Net loss per share - diluted	`EarningsPerShareDiluted`	$-0.29	USD	2 Qtrs
Net loss per share - diluted	`EarningsPerShareDiluted`	$-0.06	USD	1 Quarter

Cash Flow Statement 80 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-101.64M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-52.40M	USD	2 Qtrs
Provision for credit loss	`ProvisionForDoubtfulAccounts`	$46.00K	USD	2 Qtrs
Provision for credit loss	`ProvisionForDoubtfulAccounts`	$111.00K	USD	2 Qtrs
Provision for credit loss	`ProvisionForDoubtfulAccounts`	$38.00K	USD	1 Quarter
Provision for credit loss	`ProvisionForDoubtfulAccounts`	$58.00K	USD	1 Quarter
Loss on sublease	`LossOnSublease`	$509.00K	USD	2 Qtrs
Loss on sublease	`LossOnSublease`	-	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$7.75M	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$8.22M	USD	2 Qtrs
Amortization-debt issuance costs and investment discount	`AmortizationOfFinancingCosts`	$1.11M	USD	2 Qtrs
Amortization-debt issuance costs and investment discount	`AmortizationOfFinancingCosts`	$1.14M	USD	2 Qtrs
Payment-in-kind interest	`PaidInKindInterest`	$2.05M	USD	2 Qtrs
Payment-in-kind interest	`PaidInKindInterest`	$2.17M	USD	2 Qtrs
Equity-based compensation and common stock payments	`ShareBasedCompensationAndCommonStockPayments`	$40.15M	USD	2 Qtrs
Equity-based compensation and common stock payments	`ShareBasedCompensationAndCommonStockPayments`	$51.27M	USD	2 Qtrs
Non-cash lease expense	`OperatingLeaseCost`	$1.31M	USD	2 Qtrs
Non-cash lease expense	`OperatingLeaseCost`	$1.42M	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$25.50M	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$39.61M	USD	2 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$6.59M	USD	2 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$14.39M	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$150.00K	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-6.00K	USD	2 Qtrs
Medical expenses payable	`IncreaseDecreaseInMedicalExpensesPayable`	$47.98M	USD	2 Qtrs
Medical expenses payable	`IncreaseDecreaseInMedicalExpensesPayable`	$23.11M	USD	2 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$-2.37M	USD	2 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$-3.15M	USD	2 Qtrs
Accrued compensation	`IncreaseDecreaseInAccruedCompensation`	$940.00K	USD	2 Qtrs
Accrued compensation	`IncreaseDecreaseInAccruedCompensation`	$-2.53M	USD	2 Qtrs
Lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-2.03M	USD	2 Qtrs
Lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-1.79M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-1.28M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-61.56M	USD	2 Qtrs
Purchase of business, net of cash received	`PaymentsToAcquireAssetsInvestingActivities`	-	USD	2 Qtrs
Purchase of business, net of cash received	`PaymentsToAcquireAssetsInvestingActivities`	$1.11M	USD	2 Qtrs
Asset acquisition, net of cash received	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$1.41M	USD	2 Qtrs
Asset acquisition, net of cash received	`PaymentsToAcquireBusinessesNetOfCashAcquired`	-	USD	2 Qtrs
Purchase of investments	`PaymentsToAcquireInvestments`	$800.00K	USD	2 Qtrs
Purchase of investments	`PaymentsToAcquireInvestments`	$1.10M	USD	2 Qtrs
Sale of investments	`ProceedsFromSaleOfLongtermInvestments`	$800.00K	USD	2 Qtrs
Sale of investments	`ProceedsFromSaleOfLongtermInvestments`	$1.00M	USD	2 Qtrs
Acquisition of property and equipment	`ProceedsFromAcquisitionOfPropertyAndEquipment`	$-10.77M	USD	2 Qtrs
Acquisition of property and equipment	`ProceedsFromAcquisitionOfPropertyAndEquipment`	$-9.46M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-11.98M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-10.87M	USD	2 Qtrs
Repurchase of noncontrolling interest	`ProceedsFromPaymentsToMinorityShareholders`	$-100.00K	USD	2 Qtrs
Repurchase of noncontrolling interest	`ProceedsFromPaymentsToMinorityShareholders`	$15.00K	USD	2 Qtrs
Equity repurchase	`PaymentsForRepurchaseOfEquity`	$1.47M	USD	2 Qtrs
Equity repurchase	`PaymentsForRepurchaseOfEquity`	-	USD	2 Qtrs
Issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	-	USD	2 Qtrs
Issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$390.60M	USD	2 Qtrs
Common stock issuance costs	`PaymentsOfStockIssuanceCosts`	$29.01M	USD	2 Qtrs
Common stock issuance costs	`PaymentsOfStockIssuanceCosts`	-	USD	2 Qtrs
Net cash (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-100.00K	USD	2 Qtrs
Net cash (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$360.13M	USD	2 Qtrs
Net increase (decrease) in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$287.71M	USD	2 Qtrs
Net increase (decrease) in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$-13.37M	USD	2 Qtrs
Cash and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$495.52M	USD	Point-in-time
Cash and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$468.35M	USD	Point-in-time
Cash and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$454.98M	USD	Point-in-time
Cash and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$207.81M	USD	Point-in-time
Cash and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$495.52M	USD	Point-in-time
Cash and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$468.35M	USD	Point-in-time
Cash and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$454.98M	USD	Point-in-time
Cash and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$207.81M	USD	Point-in-time
Cash paid for interest	`InterestPaidNet`	$5.57M	USD	2 Qtrs
Cash paid for interest	`InterestPaidNet`	$5.41M	USD	2 Qtrs
Acquisition of property in accounts payable	`AcquisitionOfPropertyInAccountsPayable`	$232.00K	USD	2 Qtrs
Acquisition of property in accounts payable	`AcquisitionOfPropertyInAccountsPayable`	$418.00K	USD	2 Qtrs
Purchase of business in accounts payable	`CapitalExpendituresIncurredButNotYetPaid`	-	USD	2 Qtrs
Purchase of business in accounts payable	`CapitalExpendituresIncurredButNotYetPaid`	$240.00K	USD	2 Qtrs
Cash	`CashAndCashEquivalentsAtCarryingValue`	$453.23M	USD	Point-in-time
Cash	`CashAndCashEquivalentsAtCarryingValue`	$494.62M	USD	Point-in-time
Restricted cash in other assets	`RestrictedCashAndCashEquivalents`	$900.00K	USD	Point-in-time
Restricted cash in other assets	`RestrictedCashAndCashEquivalents`	$1.75M	USD	Point-in-time
Total	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$495.52M	USD	Point-in-time
Total	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$468.35M	USD	Point-in-time
Total	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$454.98M	USD	Point-in-time
Total	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$207.81M	USD	Point-in-time

Stockholders Equity 38 line items

Line Item	Tag	Value	Unit	Period
Common stock issuance costs	`StockIssuedDuringPeriodIssuanceCosts`	$-12.00K	USD	1 Quarter
Beginning Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$293.29M	USD	Point-in-time
Beginning Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$306.06M	USD	Point-in-time
Beginning Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$30.61M	USD	Point-in-time
Beginning Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$354.25M	USD	Point-in-time
Beginning Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$340.38M	USD	Point-in-time
Beginning Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$293.70M	USD	Point-in-time
Beginning Balance, Shares	`CommonStockSharesIssued`	187.19M	shares	Point-in-time
Beginning Balance, Shares	`CommonStockSharesIssued`	187.27M	shares	Point-in-time
Net loss attributable to Alignment Healthcare, Inc.	`NetIncomeLoss`	$-101.64M	USD	2 Qtrs
Net loss attributable to Alignment Healthcare, Inc.	`NetIncomeLoss`	$-52.40M	USD	2 Qtrs
Net loss attributable to Alignment Healthcare, Inc.	`NetIncomeLoss`	$-11.58M	USD	1 Quarter
Net loss attributable to Alignment Healthcare, Inc.	`NetIncomeLoss`	$-44.76M	USD	1 Quarter
Noncontrolling interest attributable to subsidiary	`NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance`	$15.00K	USD	2 Qtrs
Noncontrolling interest attributable to subsidiary	`NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance`	$15.00K	USD	1 Quarter
Common stock issuance costs	`StockIssuedDuringPeriodIssuanceCosts`	$-12.00K	USD	1 Quarter
Issuance of common stock, net of issuance costs	`StockIssuedDuringPeriodValueNewIssues`	$1.04M	USD	Point-in-time
Issuance of common stock, net of issuance costs	`StockIssuedDuringPeriodValueNewIssues`	$361.59M	USD	2 Qtrs
Issuance of common stock, net of issuance costs, Shares	`StockIssuedDuringPeriodSharesNewIssues`	9.20M	shares	Point-in-time
Issuance of common stock to third-party business partners	`StockIssuedDuringPeriodValueToTheThirdPartyBusinessProviders`	$6.48M	USD	2 Qtrs
Issuance of common stock to stock appreication rights holders	`StockIssuedDuringPeriodValueEmployeeBenefitPlan`	$11.51M	USD	2 Qtrs
Forfeitures	`StockIssuedDuringPeriodValueShareBasedCompensationForfeited`	-	USD	1 Quarter
Forfeitures	`StockIssuedDuringPeriodValueShareBasedCompensationForfeited`	-	USD	2 Qtrs
Equity-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$33.28M	USD	2 Qtrs
Equity-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$12.10M	USD	1 Quarter
Equity-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$30.89M	USD	1 Quarter
Equity-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$40.15M	USD	2 Qtrs
Equity repurchase	`StockRepurchasedDuringPeriodValue`	$1.47M	USD	2 Qtrs
Repurchase of noncontrolling interest attributable to subsidiary	`MinorityInterestDecreaseFromRedemptions`	$-100.00K	USD	2 Qtrs
Repurchase of noncontrolling interest attributable to subsidiary	`MinorityInterestDecreaseFromRedemptions`	$-100.00K	USD	1 Quarter
Ending Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$293.29M	USD	Point-in-time
Ending Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$306.06M	USD	Point-in-time
Ending Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$30.61M	USD	Point-in-time
Ending Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$354.25M	USD	Point-in-time
Ending Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$340.38M	USD	Point-in-time
Ending Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$293.70M	USD	Point-in-time
Ending Balance, Shares	`CommonStockSharesIssued`	187.19M	shares	Point-in-time
Ending Balance, Shares	`CommonStockSharesIssued`	187.27M	shares	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.